Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 12/20 | 0.45 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 11/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937895 | 0.84 | HTT (0.46) | — | |
| SCHEMBL11937898 | 0.84 | HTT (0.46) | — | |
| SCHEMBL13574385 | 0.83 | XIAP (0.48) | XIAPBIRC3BIRC2 | |
| SCHEMBL2439908 | 0.83 | XIAP (0.49) | XIAPBIRC3BIRC2 | |
| SCHEMBL12300017 | 0.83 | XIAP (0.49) | XIAPBIRC3BIRC2 | |
| SCHEMBL14037286 | 0.82 | BIRC2 (0.42) | XIAPBIRC3BIRC2 | |
| SCHEMBL13823041 | 0.82 | XIAP (0.43) | XIAPBIRC2MMP1MMP9MMP14 | |
| SCHEMBL13209787 | 0.81 | MMP1 (0.44) | XIAPBIRC3BIRC2MMP1MMP9 | |
| SCHEMBL20260345 | 0.81 | MMP1 (0.44) | XIAPBIRC3BIRC2MMP1MMP9 | |
| SCHEMBL21308308 | 0.81 | MMP1 (0.40) | MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023141300-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20200376035-A1 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | UNIV PENNSYLVANIA (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019165189-A1 | PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2018106870-A1 | COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-06-14 | — | — | WO | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-7517906-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | XIAP 2/4885BIRC3 4/4885BIRC2 3/4885 |
| US-20200376035-A1 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | CD47, HAVCR2, MICA | XIAP 90/4885BIRC3 36/4885BIRC2 33/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | XIAP 5/4885BIRC3 6/4885BIRC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.